United States - English - NLM (National Library of Medicine)

northstar rxllc - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none risk summary based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregna

Canada - English - Health Canada

pfizer canada ulc - sunitinib (sunitinib malate) - capsule - 37.5mg - sunitinib (sunitinib malate) 37.5mg - antineoplastic agents

Malta - English - Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 37.5 mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. risk summary based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib t

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 66.8 mg (equivalent: sunitinib, qty 50 mg) - capsule - excipient ingredients: sodium lauryl sulfate; titanium dioxide; croscarmellose sodium; shellac; povidone; magnesium stearate; sodium hydroxide; gelatin; iron oxide black; iron oxide red; propylene glycol; mannitol; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 66.8mg equivalent to sunitinib 50mg;   - capsule - 50 mg - active: sunitinib malate 66.8mg equivalent to sunitinib 50mg   excipient: croscarmellose sodium gelatin ink iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 33.4 mg (equivalent: sunitinib, qty 25 mg) - capsule - excipient ingredients: titanium dioxide; mannitol; propylene glycol; shellac; sodium lauryl sulfate; povidone; iron oxide yellow; iron oxide red; sodium hydroxide; magnesium stearate; croscarmellose sodium; iron oxide black; gelatin - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 16.7 mg (equivalent: sunitinib, qty 12.5 mg) - capsule - excipient ingredients: gelatin; sodium hydroxide; sodium lauryl sulfate; iron oxide red; magnesium stearate; shellac; povidone; titanium dioxide; propylene glycol; mannitol; croscarmellose sodium - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sunitinib - hard capsule - sunitinib 12.5 mg - antineoplastic agents

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sunitinib - hard capsule - sunitinib 25 mg - antineoplastic agents